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Results: 519 patients were randomised (S: 261, CT-S 258) from 70 
centres in the UK, the Netherlands, Germany and Belgium. The median 
age of the patients was 63 years, 72% were male, 55% were perfor-
mance status (PS) 0, 44% PS 1, 49% had squamous cell histology, 
61% had stage I, 31% stage II, and 7% stage III disease. 12% patients 
received mitomycin/vinblastine/cisplatin, 7% mitomycin/ifosfamide/
cisplatin, 45% vinorelbine/cisplatin, 12% carboplatin/docetaxel, 
and 25% cisplatin/gemcitabine. The trial showed that neo-adjuvant 
chemotherapy was feasible (76% of patients received all 3 cycles of 
chemotherapy), resulted in a good response rate (4% CR, 45% PR), and 
appeared to cause down-staging in approximately 13% of patients. The 
use of pre-operative chemotherapy did not affect the type of surgery 
performed (lobectomy: S 61%, CT-S 66%, pneumonectomy: S 32%, 
CT-S 28%), or the post-operative complication rate. Apart from a re-
duction in ‘role physical’ (problems with work or other daily activities 
as a result of physical health) in the CT-S group at 6 months, no signiﬁ-
cant differences were observed in quality of life between the treatment 
groups. The time to (and sites of) relapse did not differ between the 
regimens, except that more patients in the CT-S group developed brain 
metastases (S 16, CT-S 31). A total of 244 patients have died (S 122, 
CT-S 122), and there is no evidence of a difference in terms of overall 
survival (HR 1.02, 95% CI 0.80, 1.31). Median, 1, 2 and 5 year sur-
vival in the S group were: 54 months, 83%, 69% and 45% respectively, 
and applying the HR to these ﬁgures gives, for the CT-S group: 53 
months, 83%, 69% and 44% respectively. Exploratory analyses showed 
no evidence that any subgroup beneﬁted signiﬁcantly more or less from 
neo-adjuvant chemotherapy.
Conclusions: This intergroup trial, which is the largest trial of neo-ad-
juvant chemotherapy in patients with resectable NSCLC, indicated that 
the addition of neo-adjuvant platinum-based chemotherapy did not lead 
to a beneﬁt in overall survival.
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Background: Building on a previous IPD meta-analysis of CT (BMJ 
1995;311:899-909) which suggested that CT may have a role in the 
treatment of NSCLC, we have carried out a new, up-to-date IPD meta-
analysis. This includes RCTs, regimens and outcomes that were not 
available in 1995. This new meta-analysis examines the role of CT in 7 
treatment comparisons. Here we report the effectiveness of supportive 
care plus CT compared with supportive care alone.
Methods: We conducted a systematic search for RCTs followed by the 
central collection, checking and re-analysis of updated IPD. Results 
from individual RCTs were combined using the stratiﬁed (by trial) log 
rank test to calculate individual and pooled hazard ratios (HRs).
Results: IPD were obtained from 15 RCTs and 2666 patients. This 
adds 6 RCTs and 1702 patients to the 1995 analyses. 11 RCTs used 
cisplatin-based CT regimens, 4 RCTs used single agent CT (etoposide, 
navelbine, gemcitabine, paclitaxel). The results show a highly sig-
niﬁcant beneﬁt of CT on survival (HR=0.78 95% Conﬁdence Interval 
0.71-0.84, p<0.000001), with an absolute beneﬁt of 8% (from 20% 
to 28%) at 12 months across all patients. There was no evidence of a 
difference in effect (p=0.69) between trials that used cisplatin-based 
regimens (11 RCTs, HR=0.76), etoposide alone (1 RCT, HR=0.87) or 
newer single agents (3 RCTs, HR=0.79) (Interaction p=0.69). There 
was no evidence that any patient subgroup deﬁned by age, sex, stage or 
histology beneﬁted more or less from CT. However, owing to differing 
underlying survival rates, the absolute beneﬁt of CT at 12 months did 
vary according to WHO/ECOG (or equivalent) performance status. PS 
0=8% (from 26% to 34%), PS 1=8% (from 18% to 26%), PS 2=5% 
(from 6% to 11%) and PS 3=4% (from 5% to 9%).
Conclusion: The results demonstrate a substantial and consistent rela-
tive beneﬁt of CT in advanced NSCLC. The effectiveness of newer 
agents such as navelbine, paclitaxel and gemcitabine (used as single 
agents) appears to be similar to that of cisplatin combined with older 
agents such as vindesine and mitomycin C. The absolute effect of CT 
varied according to performance status.
B2-04 Cytotoxic Chemotherapy II, Tue, 13:45 - 15:30
Single agent versus combination therapy in advanced NSCLC 
patients with performance status 2: Results from a regression 
analysis of STELLAR 3 and 4
Lilenbaum, Rogerio1 Bandstra, Bruce2 Langer, Corey3 O’Byrne, 
Kenneth4 O’Brien, Mary5 Ross, Helen6 Socinski, Mark7 Oldham, Fred2 
Singer, Jack2 Bonomi, Philip8 
1 Mount Sinai Comprehensive Cancer Center, Miami, FL, USA 2 CTI, 
Inc., Seattle, WA, USA 3 Fox Chase Cancer Center, Philadelphia, PA, 
USA 4 St. James Hospital, Dublin, Ireland 5 Royal Marsden Hospital, 
London, UK 6 Earle A. Chiles Research Institute, Portland, OR, USA 7 
Lineberger Comprehensive Cancer Center, University of North Caro-
lina, Chapel Hill, NC, USA 8 Rush University Medical Center, Chicago, 
IL, USA 
Background: Divergent opinions exist whether patients who present 
with advanced NSCLC and performance status (PS) 2 beneﬁt from ei-
ther standard doublet chemotherapy or, due to treatment-related toxicity 
and limited survival potential, single agent therapy is more appropriate 
in these pts. 
Methods: Linear regression analysis of the data from the two largest 
phase 3 trials of de novo therapy in PS 2 pts, STELLAR 3 and 4, was 
performed to identify patient subsets that would beneﬁt from either 
doublet or singlet therapy. STELLAR 3 randomized 400 pts to either 
paclitaxel + carboplatin or paclitaxel poliglumex (PPX) + carboplatin. 
STELLAR 4 randomized 396 patients to single agent PPX or to investi-
gator choice of single agent vinorelbine or gemcitabine. Both trials had 
identical inclusion and exclusion criteria. Both arms of each trial had 
similar outcomes (HR = 0.95 and 0.97; PPX to control for STELLAR 3 
and 4, respectively). 
Results: In the univariate model, signiﬁcant predictors of compromised 
survival (p ≤ 0.01) were: albumin <3.5 gm, extrathoracic metastases 
excluding brain (ETM), hemoglobin <11 gm, weight loss >5%, LDH 
>200 IU, geographic region (US v. rest of world), any tobacco his-
tory, > 2 comorbid conditions, and disease stage (4 versus <4). In the 
multivariate model, only albumin, ETM, >2 comorbidities, and tobacco 
history were signiﬁcant (p <0.0001). Patients with none of these four 
risk factors had median survival of 473 days; survival decreased in a 
stepwise manner to 96 days in pts with all four risk factors. To analyze 
the effect of singlet v. doublet therapy on outcome, pts with three or 
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four factors were compared to those with two or fewer. Pts with more 
than two risk factors had a signiﬁcantly shorter survival (276 v. 169 
days; HR= 1.93, p<0.0001). Outcome did not differ between single v. 
doublet therapy in lower risk pts (median survivals 271 v. 286 days, 
whereas higher risk pts showed a trend toward increased estimated 
median survival increased with doublet therapy (186 v. 148 days; HR= 
0.84, p=0.16). 
Conclusions: These data suggest that stratiﬁcation using these clinical 
factors may be appropriate in future trials. PS 2 patients deﬁned as 
higher risk by these factors may beneﬁt from more intensive therapy; in 
contrast, pts with two or fewer risk factors may not gain further clinical 
beneﬁt from more intensive therapy. 
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Background: WBRT followed by CTx is commonly used for NSCLC 
patients (pts) with brain metastasis. However, when neurologic symp-
toms or signs are absent or controlled by supportive care, CTx could 
be a choice of treatment. We conducted a randomized trial of frontline 
CTx compared with WBRT in this clinical setting whether frontline 
CTx was feasible and its efﬁcacy and toxicity proﬁle as well as quality 
of life and survival outcome was affected by the time of WBRT.
Methods: The eligibility criteria are as follows: pathologic conﬁrmed 
NSCLC, stage IV with brain metastasis at ﬁrst diagnosis, age 18-75, 
ECOG PS 0-2, and adequate organ functions. After stratiﬁed according 
to PS (ECOG 0-1 vs 2), the number of intracranial metastases (<3 vs 
3≤) and presence of extrathoracic extracranial metastasis, eligible pts 
were randomized to the two arms; Arm A, CTx followed by WBRT; 
Arm B, WBRT followed by CTx. CTx consisted of gemcitabine 900 
mg/m2 and vinorelbine 25 mg/m2 on D1 & 8 q 3 wk, up to 6 cycles. 
WBRT consisted of 30Gy/10fx/12d. We assessed tumor response, 
toxicity proﬁle and quality of life according to WHO response criteria, 
NCICTC and EORTC C-30/LC-13 questionaire, respectively.
Results: Between 2002 Aug and 2005 Nov, 48 pts were enrolled. All of 
25 pts in Arm A received CTx and WBRT, while 4 (17%) of 23 pts in 
Arm B could not receive CTx due to deterioration of PS or death dur-
ing or immediately after WBRT. Intracranial tumor responses to CTx 
in Arm A were closely correlated with extracranial responses (k=0.82). 
There were no statistically signiﬁcant differences in overall response 
rate (28% vs. 43%), time-to-progression (6.4 mo vs 6.3 mo) and 
survival (9.1 mo vs 9.9 mo). However, grade 3/4 neutropenia occurred 
more frequently in Arm B (79% vs 40%, p=0.014). Cognitive function 
deteriorated during frontline CTx, while it did not deteriorate during 
CTx after WBRT although the score already lowered after WBRT.
Conclusions: Frontline chemotherapy can be an appropriate treatment 
when neurologic symptoms or signs are absent or controlled by sup-
portive care. The timing and the real need for WBRT should be deﬁned 
in further trials.
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Background: Platinum and gemcitabine chemotherapy for NSCLC is 
usually administered with cisplatin or carboplatin on day 1 and gem-
citabine on days 1 and 8 of a 21 day cycle. Cisplatin administration is 
resource intensive for treatment facilities and nursing time due to ﬂuid 
hydration required to prevent nephrotoxicity. Carboplatin is conve-
niently administered over 30 minutes to 1 hour without ﬂuid hydration, 
is less nephrotoxic, neurotoxic and emetogenic, but haematological 
toxicity may be greater. A fractionated regimen of cisplatin 35mg/m2 
administered on days 1 and 8 of each cycle can be given without 
extended hydration regimens, may be less toxic, and of similar efﬁcacy. 
We conducted this multicentre, randomised, phase III trial to compare 
hospitalisation rates for treatment of toxicity between Gemcitabine 
1250mg/m2 iv and cisplatin 35mg/m2 iv day 1 and 8 (GCis) every 21 
days and Gemcitabine 1250mgs/m2 iv days 1 and 8 and carboplatin at a 
dosage of AUC 5 day 1(GCarbo) every 21 days, for a total of 4 cycles, 
in patients with NSCLC. 
Methods: Eligible patients had inoperable stage III or IV NSCLC, KPS 
greater than or equal to 50, and adequate organ function. Patients were 
stratiﬁed by disease stage and performance status. The primary endpoint 
was hospitalisation for treatment of toxicity. The study had 90% power to 
detect a reduction in extra overnight stays from 30 to 15% requiring 400 
patients. Secondary objectives included overall survival and toxicity.
Results: 400 patients were randomised between Nov 2002 and Aug 
2006. Currently 350 patients are evaluable for the primary objective. A 
total of 603 and 614 cycles were administered to patients on the GCis 
and GCarbo arms, respectively. The number of overnight stays required 
for chemotherapy administration did not differ with only ﬁve patients 
in the GCis arm and eight patients in the GCarbo arm, p=0.08. Other 
overnight stays were required by 51 (28%) patients who were treated 
with GCis and 68 (40%) patients who received GCarbo (p=0.04). There 
was no difference in the number of days of iv antibiotics adminis-
tered, p=0.41. There were signiﬁcantly more patients requiring blood 
and platelet transfusions in the GCarbo arm with 53% of patients 
requiring at least one blood transfusion (p=0.01) and 22% requiring 
platelets(p=0.002). Patients on GCis reported more nausea, p=0.04, and 
peripheral neuropathy, p=0.008 whereas patients on GCarbo reported 
more rash, p=0.008. The majority were grade 1 and 2 toxicities. There 
were no differences in vomiting, alopecia, mucositis, infection, renal 
toxicity, tinnitus, ﬂu like symptoms, oedema, deafness or ﬂushing. 
There was no difference in survival, median 9.1 and 9.5 months 
(p=0.41) with 1-year survival at 39% and 42% for GCis and GCarbo, 
respectively.
Conclusion: This preliminary analysis demonstrates that fractionated 
cisplatin treatment with gemcitabine can be given safely to an outpa-
tient and is well tolerated, with signiﬁcantly less requirement for blood 
and platelet transfusions, and similar survival outcome to that of the 
GCarbo regimen. An updated analysis will be available later this year.
